These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9559305)

  • 21. Effects of combined fluoxetine and counseling in the outpatient treatment of cocaine abusers.
    Covi L; Hess JM; Kreiter NA; Haertzen CA
    Am J Drug Alcohol Abuse; 1995 Aug; 21(3):327-44. PubMed ID: 7484983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.
    Lin CH; Lane HY; Chen CC; Juo SH; Yen CF
    Clin J Pain; 2011; 27(9):805-10. PubMed ID: 21677571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Toxic tricyclic drug plasma level caused by fluoxetine].
    Hambrecht M
    Psychiatr Prax; 1995 Nov; 22(6):252-3. PubMed ID: 8570758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.).
    Shoulson RL; Stark RL; Garland M
    J Am Assoc Lab Anim Sci; 2014 Nov; 53(6):708-16. PubMed ID: 25650979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personality disorders improve in patients treated for major depression.
    Mulder RT; Joyce PR; Frampton CM
    Acta Psychiatr Scand; 2010 Sep; 122(3):219-25. PubMed ID: 19895619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
    Papakostas GI; Petersen T; Denninger JW; Montoya HD; Nierenberg AA; Alpert JE; Fava M
    Ann Clin Psychiatry; 2003; 15(3-4):187-92. PubMed ID: 14971864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of medical comorbidity on acute treatment in major depressive disorder.
    Iosifescu DV; Nierenberg AA; Alpert JE; Smith M; Bitran S; Dording C; Fava M
    Am J Psychiatry; 2003 Dec; 160(12):2122-7. PubMed ID: 14638581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma catecholamine levels after fluoxetine treatment in depressive patients.
    Blardi P; de Lalla A; Auteri A; Iapichino S; Dell'Erba A; Castrogiovanni P
    Neuropsychobiology; 2005; 51(2):72-6. PubMed ID: 15741747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of fluoxetine in elderly men and women.
    Ferguson JM; Hill H
    Gerontology; 2006; 52(1):45-50. PubMed ID: 16439824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Anna Clark L; Thase ME; Jarrett RB
    Psychiatry Res; 2017 Jul; 253():174-181. PubMed ID: 28388454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine.
    Norman TR; Gupta RK; Burrows GD; Parker G; Judd FK
    Int Clin Psychopharmacol; 1993; 8(1):25-9. PubMed ID: 8473717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
    Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
    Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationships between low red blood cell count and clinical response to fluoxetine in depressed elderly patients.
    Mentré F; Golmard JL; Launay JM; Aubin-Brunet V; Bouhassira M; Jouvent R
    Psychiatry Res; 1998 Dec; 81(3):403-5. PubMed ID: 9925192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
    Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
    Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
    Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania.
    Megna JL; Devitt PJ
    Ann Pharmacother; 2001 Jan; 35(1):45-7. PubMed ID: 11197585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.